{
    "xml": "<topic id=\"PHP2964\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/retigabine\" basename=\"retigabine\" title=\"RETIGABINE\">\n<title>RETIGABINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1195\" namespace=\"/interactions/list-of-drug-interactions/antiepileptics/retigabine\">Retigabine</xref>\n</p>\n<data name=\"vtmid\">704476003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_926692410\" title=\"Antiepileptics\">Antiepileptics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP57960\" outputclass=\"indicationsAndDose\" rev=\"1.12\" parent=\"/drugs/retigabine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive treatment of drug-resistant focal seizures with or without secondary generalisation when other appropriate drug combinations have proved inadequate or have not been tolerated</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially up to 300&#8239;mg daily in 3 divided doses, then increased in steps of up to 150&#8239;mg every 1&#8239;week, adjusted according to response; maintenance 0.6&#8211;1.2&#8239;g daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 150&#8239;mg daily in 3 divided doses, then increased in steps of up to 150&#8239;mg every 1&#8239;week, adjusted according to response; maximum 900&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58113\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/retigabine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Known QT-interval prolongation</ph>; <ph outputclass=\"caution\">risk of urinary retention</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">QT-interval prolongation</p>\n<p>Patients with known QT-interval prolongation, or with the following risk factors for QT interval prolongation, should be carefully monitored while taking retigabine: cardiac failure, ventricular hypertrophy, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57950\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/retigabine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (retigabine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57879\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/retigabine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Amnesia</ph>; <ph outputclass=\"sideEffect\">anxiety</ph>; <ph outputclass=\"sideEffect\">blurred vision</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diplopia</ph>; <ph outputclass=\"sideEffect\">discoloration of lips</ph>; <ph outputclass=\"sideEffect\">discoloration of nails</ph>; <ph outputclass=\"sideEffect\">discoloration of ocular tissue</ph>; <ph outputclass=\"sideEffect\">discoloration of skin</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dry mouth</ph>; <ph outputclass=\"sideEffect\">dysuria</ph>; <ph outputclass=\"sideEffect\">haematuria</ph>; <ph outputclass=\"sideEffect\">impaired attention</ph>; <ph outputclass=\"sideEffect\">impaired coordination</ph>; <ph outputclass=\"sideEffect\">impaired speech</ph>; <ph outputclass=\"sideEffect\">increased appetite</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">myoclonus</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">psychosis</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>; <ph outputclass=\"sideEffect\">visual impairment</ph>; <ph outputclass=\"sideEffect\">weight gain</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dyspepsia</ph>; <ph outputclass=\"sideEffect\">dysphagia</ph>; <ph outputclass=\"sideEffect\">hypokinesia</ph>; <ph outputclass=\"sideEffect\">nephrolithiasis</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">suicidal ideation</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">urinary retention</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57983\" outputclass=\"hepaticImpairment\" parent=\"/drugs/retigabine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose by 50% in moderate to severe impairment; increase by 50&#8239;mg every week according to response up to maximum 600&#8239;mg daily (450&#8239;mg in elderly).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57907\" outputclass=\"renalImpairment\" parent=\"/drugs/retigabine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose by 50% if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; increase by 50&#8239;mg every week according to response up to maximum 600&#8239;mg daily (450&#8239;mg in elderly).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57828\" outputclass=\"monitoringRequirements\" parent=\"/drugs/retigabine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">Ophthalmological monitoring</p>\n<p>A comprehensive ophthalmological examination (including visual acuity test, slit-lamp examination, and dilated fundoscopy) should be performed at initiation of treatment and at least every 6 months thereafter during treatment. Changes in vision or retinal pigment should lead to re-assessment of the benefits and risks of continuing treatment&#8212;discontinue unless no other treatment options are available. Monitoring should be increased if treatment is continued.</p>\n<p>Monitor for discoloration of ocular tissue and visual impairment.</p>\n<p>Monitor for blue-grey discoloration of nails, lips and skin&#8212;continue treatment only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57720\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.10\" parent=\"/drugs/retigabine\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Switching between formulations</p>\n<p>Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p>\n<p>Patients may need to be maintained on a specific manufacturer&#8217;s branded or generic retigabine product.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57798\" outputclass=\"nationalFunding\" rev=\"1.24\" parent=\"/drugs/retigabine\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA232</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (July 2011)</p>\r\n<p>Retigabine is recommended as an option for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and older with epilepsy, only when previous treatment with carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, and topiramate has not provided an adequate response, or has not been tolerated.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA232\">www.nice.org.uk/TA232</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (June 2011) that retigabine (<i>Trobalt <tm tmtype=\"reg\"/>\r\n</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland as adjunctive therapy in adults with focal seizures with or without secondary generalisation. It is restricted for use in refractory epilepsy.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP2964-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/retigabine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76209\" title=\"Tablet\" namespace=\"/drugs/retigabine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101302\" title=\"Not applicable\" namespace=\"/drugs/retigabine/not-applicable\">Not applicable</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78230\" namespace=\"/treatment-summaries/epilepsy\" title=\"Epilepsy\" count=\"1\" rel=\"backlink\">Epilepsy</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1195\" namespace=\"/interactions/list-of-drug-interactions/antiepileptics/retigabine\" title=\"Retigabine\" count=\"1\" rel=\"link\">Retigabine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76209\" namespace=\"/drugs/retigabine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101302\" namespace=\"/drugs/retigabine/not-applicable\" title=\"Not applicable\" count=\"1\" rel=\"link\">Not applicable</xref>\n</links>\n</topic>",
    "id": "PHP2964",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/retigabine",
    "basename": "retigabine",
    "title": "RETIGABINE",
    "interactants": [
        {
            "id": "bnf_int_1195",
            "label": "Retigabine"
        }
    ],
    "vtmid": "704476003",
    "drugClassification": [
        "Antiepileptics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Adjunctive treatment of drug-resistant focal seizures with or without secondary generalisation when other appropriate drug combinations have proved inadequate or have not been tolerated",
                        "html": "Adjunctive treatment of drug-resistant focal seizures with or without secondary generalisation when other appropriate drug combinations have proved inadequate or have not been tolerated"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially up to 300 mg daily in 3 divided doses, then increased in steps of up to 150 mg every 1 week, adjusted according to response; maintenance 0.6&#8211;1.2 g daily.",
                        "html": "<p>Initially up to 300&#8239;mg daily in 3 divided doses, then increased in steps of up to 150&#8239;mg every 1&#8239;week, adjusted according to response; maintenance 0.6&#8211;1.2&#8239;g daily.</p>"
                    },
                    {
                        "textContent": "Initially 150 mg daily in 3 divided doses, then increased in steps of up to 150 mg every 1 week, adjusted according to response; maximum 900 mg per day.",
                        "html": "<p>Initially 150&#8239;mg daily in 3 divided doses, then increased in steps of up to 150&#8239;mg every 1&#8239;week, adjusted according to response; maximum 900&#8239;mg per day.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Known QT-interval prolongation",
                "html": "Known QT-interval prolongation"
            },
            {
                "type": "cautions",
                "textContent": "risk of urinary retention",
                "html": "risk of urinary retention"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "QT-interval prolongation",
                "textContent": "Patients with known QT-interval prolongation, or with the following risk factors for QT interval prolongation, should be carefully monitored while taking retigabine: cardiac failure, ventricular hypertrophy, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval.",
                "html": "<p>Patients with known QT-interval prolongation, or with the following risk factors for QT interval prolongation, should be carefully monitored while taking retigabine: cardiac failure, ventricular hypertrophy, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (retigabine).",
                "html": "<p>Appendix 1 (retigabine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Amnesia",
                        "html": "Amnesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anxiety",
                        "html": "anxiety",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "blurred vision",
                        "html": "blurred vision",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diplopia",
                        "html": "diplopia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "discoloration of lips",
                        "html": "discoloration of lips",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "discoloration of nails",
                        "html": "discoloration of nails",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "discoloration of ocular tissue",
                        "html": "discoloration of ocular tissue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "discoloration of skin",
                        "html": "discoloration of skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry mouth",
                        "html": "dry mouth",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dysuria",
                        "html": "dysuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haematuria",
                        "html": "haematuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "impaired attention",
                        "html": "impaired attention",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "impaired coordination",
                        "html": "impaired coordination",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "impaired speech",
                        "html": "impaired speech",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increased appetite",
                        "html": "increased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myoclonus",
                        "html": "myoclonus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "psychosis",
                        "html": "psychosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "visual impairment",
                        "html": "visual impairment",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight gain",
                        "html": "weight gain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dyspepsia",
                        "html": "Dyspepsia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dysphagia",
                        "html": "dysphagia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypokinesia",
                        "html": "hypokinesia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nephrolithiasis",
                        "html": "nephrolithiasis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "suicidal ideation",
                        "html": "suicidal ideation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "urinary retention",
                        "html": "urinary retention",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        }
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose by 50% in moderate to severe impairment; increase by 50 mg every week according to response up to maximum 600 mg daily (450 mg in elderly).",
                "html": "<p>Reduce dose by 50% in moderate to severe impairment; increase by 50&#8239;mg every week according to response up to maximum 600&#8239;mg daily (450&#8239;mg in elderly).</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose by 50% if eGFR less than 50 mL/minute/1.73 m2; increase by 50 mg every week according to response up to maximum 600 mg daily (450 mg in elderly).",
                "html": "<p>Reduce dose by 50% if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; increase by 50&#8239;mg every week according to response up to maximum 600&#8239;mg daily (450&#8239;mg in elderly).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "Ophthalmological monitoring",
                "textContent": "A comprehensive ophthalmological examination (including visual acuity test, slit-lamp examination, and dilated fundoscopy) should be performed at initiation of treatment and at least every 6 months thereafter during treatment. Changes in vision or retinal pigment should lead to re-assessment of the benefits and risks of continuing treatment&#8212;discontinue unless no other treatment options are available. Monitoring should be increased if treatment is continued.\n\nMonitor for discoloration of ocular tissue and visual impairment.\n\nMonitor for blue-grey discoloration of nails, lips and skin&#8212;continue treatment only if potential benefit outweighs risk.",
                "html": "<p>A comprehensive ophthalmological examination (including visual acuity test, slit-lamp examination, and dilated fundoscopy) should be performed at initiation of treatment and at least every 6 months thereafter during treatment. Changes in vision or retinal pigment should lead to re-assessment of the benefits and risks of continuing treatment&#8212;discontinue unless no other treatment options are available. Monitoring should be increased if treatment is continued.</p><p>Monitor for discoloration of ocular tissue and visual impairment.</p><p>Monitor for blue-grey discoloration of nails, lips and skin&#8212;continue treatment only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "title": "Switching between formulations",
                "textContent": "Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.\n\nPatients may need to be maintained on a specific manufacturer&#8217;s branded or generic retigabine product.",
                "html": "<p>Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p><p>Patients may need to be maintained on a specific manufacturer&#8217;s branded or generic retigabine product.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA232",
                        "label": "www.nice.org.uk/TA232"
                    }
                ],
                "fundingIdentifier": "NICE TA232",
                "textContent": "Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (July 2011) Retigabine is recommended as an option for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and older with epilepsy, only when previous treatment with carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, and topiramate has not provided an adequate response, or has not been tolerated.\n\nwww.nice.org.uk/TA232",
                "html": "<p outputclass=\"title\">Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (July 2011)</p> <p>Retigabine is recommended as an option for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and older with epilepsy, only when previous treatment with carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, and topiramate has not provided an adequate response, or has not been tolerated.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA232\">www.nice.org.uk/TA232</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76209",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP101302",
                "label": "Not applicable",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78230",
                "label": "Epilepsy",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1195",
                "label": "Retigabine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76209",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP101302",
                "label": "Not applicable",
                "type": "medicinalForm"
            }
        ]
    }
}